When managing patients newly diagnosed with nonvalvular atrial fibrillation (NVAF), it is imperative for clinicians to discuss the diagnosis, evaluate individual stroke and bleeding risks, and use this information to guide therapeutic decisions. Counseling patients on a new NVAF diagnosis and discussing the need for stroke preventive therapy and available treatment options is a critical part of NVAF management that can be challenging when providing care via telemedicine.
This CME Outfitters BriefCase focuses on managing patients with NVAF via telemedicine, including discussion on treatment, clinical efficacy and safety of oral anticoagulants, selecting appropriate anticoagulation at the appropriate dose, applying the latest recommendations for patients who have undergone PCI, and how to implement best practices for a “webside manner” when providing virtual, telemedicine care.
At the end of this CME/CE activity, participants should be able to apply best practices for management of stroke risk in patients with NVAF when providing care via telemedicine.
The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize best practices for management of stroke risk in patients with NVAF when providing care via telemedicine.
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Primary care physicians, cardiologists, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Turakhia reports that he receives grants from the American Heart Association; Apple Inc.; Bayer; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardiva Medical, Inc.; Janssen Pharmaceuticals, Inc.; and SentreHEART, Inc. He is a consultant for Abbott; BIOTRONIK, Inc.; Cardiva Medical, Inc.; iRhythm Technologies, Inc.; Johnson & Johnson; Medtronic; Milestone Pharmaceuticals, Inc.; MyoKardia, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Sanofi. He receives other financial or material support as an editor for JAMA Cardiology.
Dr. Ruff reports that he receives research grants to the TIMI Study Group through Brigham and Women’s Hospital: Anthos Therapeutics; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; and National Institutes of Health. He is on Scientific Ad Boards and a consultant for Anthos Therapeutics; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Portola Pharmaceuticals, Inc.
Dr. Savoy has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-111-H01-P
Call us at (877) CME-PROS or (877) 263-7767.